Oncology - Publications - Faculty & Research - Harvard Business School

Filter Results: (62)

Filter Results: (62)

Show Results For

Page 1 of 62 Results →

Article

Missing the Near Miss: Recognizing Valuable Learning Opportunities in Radiation Oncology

By: Palak Kundu, Olivia Jung, Luca F. Valle, Amy C. Edmondson, Nzhde Agazaryan, John Hegde, Michael Steinberg and Ann Raldow

“Near miss” events are valuable low-cost learning opportunities in radiation oncology as they do not result in patient harm and are more pervasive than adverse events that do. Near misses vary depending on the presence of a latent error of behavior or process, and the... View Details

Keywords: Radiation Oncology; Cognitive Biases; Health Care and Treatment; Learning

Find at Harvard

Awards

Exceptional Women in Oncology Award

Winner of the 2017 Exceptional Women in Oncology Award for Advocacy from the Practical Recommendations in Immuno and Molecular Oncology (PRIMO) Education. View Details

January 2023
Case

Cleave Therapeutics: Taking a Risk on Oncology Drug Discovery

By: Regina Herzlinger and Brian Walker

What should a successful executive (HBS Baker Scholar) assess as her next move as the CEO of a firm with a promising and yet uncertain new drug? Amy Burroughs’ mandate to successfully commercialize Cleave Therapeutics’ drug for a cancer with no current successful... View Details

Keywords: Product Development; Leadership; Health Testing and Trials; Research and Development; Risk and Uncertainty; Financial Condition; Partners and Partnerships; Pharmaceutical Industry

Article

Psychological Safety and Near Miss Events in Radiation Oncology

By: Palak Kundu, Olivia Jung, Kathy Rose, Chonlawan Khaothiemsang, Nzhde Agazaryan, Amy C. Edmondson, Michael L. Steinberg and Ann C. Raldow

Background: Near miss events, defined as harm averted due to chance, are learning opportunities in radiation oncology. Psychological safety is a feature of a learning environment characterized by interpersonal risk taking. We examine the effects of near miss type and... View Details

November 12, 2018
Article

Precision Medicine Has Transformed Cancer Treatment. Here's How to Move It Beyond Oncology

By: Richard G. Hamermesh and Kathy Giusti

12 Nov 2018
News

Precision Medicine Has Transformed Cancer Treatment. Here’s How to Move It Beyond Oncology

Article

Resilience vs. Vulnerability: Psychological Safety and Reporting of Near Misses with Varying Proximity to Harm in Radiation Oncology

By: Palak Kundu, Olivia Jung, Amy C. Edmondson, Nzhde Agazaryan, John Hegde, Michael Steinberg and Ann Raldow

Background
Psychological safety, a shared belief that interpersonal risk taking is safe, is an important determinant of incident reporting. However, how psychological safety affects near-miss reporting is unclear, as near misses contain contrasting cues that... View Details

Keywords: Psychological Safety; Near-miss Reporting; Health Care and Treatment; Safety

September 2016
Article

Value Based Care and Bundled Payments: Anesthesia Care Costs for Outpatient Oncology Surgery Using Time-driven Activity-based Costing

By: Katy E. French, Alexis B. Guzman, Augustin C. Rubio, John C. Frenzel and Thomas Feeley

Background: With the movement towards bundled payments, stakeholders should know the true cost of the care they deliver. Time-driven activity-based costing (TDABC) can be used to estimate costs for each episode of care. In this analysis, TDABC is used to both... View Details

Keywords: Cost; Insurance; Health Care and Treatment; Insurance Industry; Health Industry

Find at Harvard

Precision Medicine Has Transformed Cancer Treatment. Here’s How to Move It Beyond Oncology

September 2012
Supplement

Intraoperative Radiotherapy for Breast Cancer (B)

The intraoperative radiotherapy (IORT) business at Carl Zeiss Meditec had struggled with growth since the time of the (A) case. Though the unit had grown revenues in excess of 50% and had exceeded its EBIT target, it faced several key strategic choices. Should it... View Details

Keywords: Radiotherapy; Breast Cancer; Brachytherapy; Therapeutic Radiation; Oncology; Oncology Treatment Systems; Elekta AB; Varian Medical Systems; Xoft; Electronic Brachytherapy; Intraoperative Radiotherapy; Disruptive Innovation; Health Care and Treatment; Entrepreneurship; Technological Innovation; Growth and Development Strategy; Health Industry; Germany

May 2014
Case

Health Care Accountability: Examples in Cancer Treatment

By: Regina E. Herzlinger and Natalie Kindred

This case is designed to support a discussion of the importance of outcomes evidence in empowering the public to make better health care decisions, the desired level of transparency and accountability for health care providers, and the issues with current measuring and... View Details

Keywords: Accountability; Health Care; Cancer; Cancer Treatment; Memorial Sloan Kettering Cancer Center; Cancer Treatment Centers Of America; Vantage Oncology; Radiology; Risk Adjustment; Treatment Outcomes; Health Care Outcomes; Prostate Cancer; Transparency; Health Care and Treatment; Risk Management; Outcome or Result; Health Industry; United States

December 2013 (Revised February 2014)
Supplement

Reinventing Brainlab (B)

By: Regina E. Herzlinger and Karol Misztal

The management of Germany's Brainlab AG, a leading provider of software-driven oncology and surgery solutions, needs to evaluate strategic options for proceeding without an exclusive hardware partner in its most profitable business segment. View Details

Keywords: Strategy; Information Infrastructure; Applications and Software; Medical Specialties; Information Technology Industry; Health Industry; Germany

September 2012 (Revised March 2014)
Case

Reinventing Brainlab (A)

By: Regina E. Herzlinger, Vincent Dessain and Karol Misztal

The management of Germany's Brainlab AG, a leading provider of software-driven oncology and surgery solutions, needs to evaluate strategic options for proceeding without an exclusive hardware partner in its most profitable business segment. View Details

Keywords: Strategy; Information Infrastructure; Applications and Software; Medical Specialties; Health Care and Treatment; Information Technology Industry; Health Industry; Germany

August 2012 (Revised August 2014)
Case

Cancer Treatment Centers of America® (A)

By: Regina E. Herzlinger and Natalie Kindred

Cancer Treatment Centers of America (CTCA), a U.S. network of four privately owned oncology focused factory hospitals, was weighing options for growth. CTCA was entirely cancer focused and specialized in treating patients with complex and advanced-stage cancers, who... View Details

14 Jan 2020
Video

Meet Enrique | CORe Participant Testimonial

December 2020 (Revised April 2021)
Case

IBM Watson at MD Anderson Cancer Center

By: Shane Greenstein, Mel Martin and Sarkis Agaian

After discovering that their cancer diagnostic tool, designed to leverage the cloud computing power of IBM Watson, needed greater integration into the clinical processes at the MD Anderson Cancer Center, the development team had difficult choices to make. The Oncology... View Details

Keywords: Decision Making; Innovation Strategy; Knowledge Management; Knowledge Use and Leverage; Operations; Failure; Information Technology; Applications and Software; Health Care and Treatment; Product Development; Health Industry; Information Technology Industry; Technology Industry; United States; Houston; Texas

January 2017 (Revised October 2018)
Case

Novartis: A Transformative Deal

By: David Collis and Ashley Hartman

When Joe Jimenez became CEO of Swiss-based Novartis in 2010, replacing longtime CEO Dan Vasella, he assumed control of one of the top pharmaceutical companies in the world. Vasella, an avowed advocate of diversification, had expanded the scope of the company and... View Details

Keywords: Novartis; GlaxoSmithKline; Asset Swap; Acquisitions; Divestiture; Strategy Alignment; Pharmaceuticals; Strategy; Business Strategy; Corporate Strategy; Diversification; Consolidation; Mergers and Acquisitions; Pharmaceutical Industry

April 2003 (Revised October 2004)
Case

Novartis: The Challenge of Success (A)

By: Sandra J. Sucher and Stacy McManus

Preliminary results from Phase 1 clinical trials of a newly developed compound, STI571, showed that 31 out of 31 patients with chronic myelogenous leukemia (CML) had their blood counts return to normal. In the world of oncology, this was unheard of. This was the... View Details

Keywords: Decision Making; Health Testing and Trials; Innovation and Invention; Markets; Distribution; Product Development; Production; Problems and Challenges; Research; Research and Development; Complexity; Biotechnology Industry; Pharmaceutical Industry

January 2001 (Revised July 2003)
Case

Pharmacyclics: Financing Research & Development

By: Malcolm P. Baker, Richard S. Ruback and Aldo Sesia

Pharmacyclics (NASDAQ: PCYC), a pharmaceutical company that manufactures products that will improve existing therapeutic treatments for cancer, arteriosclerosis, and retinal disease, was considering a $60 million private placement in February 2000. The company had more... View Details

Keywords: Valuation; Cash Flow; Financing and Loans; Business Startups; Financial Strategy; Medical Devices and Supplies Industry; Pharmaceutical Industry; Health Industry

15 Apr 2014
First Look

First Look: April 15

Purchase this case: http://hbr.org/product/pepsico-profits-and-food-the-belt-tightens/an/314055-PDF-ENG Harvard Business School Case 313-012 Cancer Treatment Centers of America® (A) Cancer Treatment Centers of America (CTCA), a U.S. network of four privately owned... View Details

Keywords: Sean Silverthorne

1
2
3
4
→